<div id="readability-page-1"> <time datetime="2025-10-15T18:36:00.000Z"> 10/15/2025 - 02:36 PM </time> Nasdaq Hearing Cancellation and Continued ListingFOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff’s delisting determination. The Company today announced that it had received a letter from Nasdaq on October 14, 2025, notifying Apollomics the Staff had determined that the Company is in compliance with Nasdaq’s continued listing requirements. Accordingly, Nasdaq has cancelled its appeal hearing and the Company’s securities will remain listed and continue to trade on The Nasdaq Stock Market. About Apollomics Inc. Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit www.apollomicsinc.com. Cautionary Statement Regarding Forward-Looking Statements This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib, future proceedings with respect to the Cayman Litigation, or the appeal of, response to, or outcome of the Nasdaq delisting notification, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVME5qSTFPU00zTVRrM05qVTRJekl4TWpJM05qQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVME5qSTFPU00zTVRrM05qVTRJekl4TWpJM05qQT0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGNkMGM2NzQtYTQxNi00ZTMyLWE2ZWEtYmMxNTVhOWQ0ZjU2LTExMzQzMzEtMjAyNS0xMC0xNS1lbg==/tiny/Apollomics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGNkMGM2NzQtYTQxNi00ZTMyLWE2ZWEtYmMxNTVhOWQ0ZjU2LTExMzQzMzEtMjAyNS0xMC0xNS1lbg==/tiny/Apollomics-Inc-.png"/> <pre>Investor Contacts:Apollomics:Peter Lin, Chief Financial OfficerApollomics, Inc.Phone: 1-650-209-4055Email: peter.lin@apollomicsinc.com</pre> </div>

APLM

Apollomics Inc. announced that it will continue to be listed on The Nasdaq Stock Market after receiving a letter from Nasdaq confirming compliance with listing requirements. This follows the cancellation of a scheduled hearing regarding a previous delisting notification. Apollomics is focused on developing oncology therapies, including its lead program, vebreltinib, for treating non-small cell lung cancer. The company emphasizes that forward-looking statements in the release are subject to risks and uncertainties.

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation | APLM Stock News